Jean Rommelaere

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial

Karsten Geletneky, Jacek Hajda, Assia L. Angelova et al. · Molecular Therapy · 2017 · 259 citations · Full text

Medicine, Immunology, Oncology +16

Characterization and mapping of RNase T1-resistant oligonucleotides derived from the genomes of Akv and MCF murine leukemia viruses.

Jean Rommelaere, Douglas V. Faller, Nancy Hopkins · Proceedings of the National Academy of Sciences · 1978 · 201 citations · Full text

Life Sciences, Biology, Molecular Biology +16

Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non‐structural proteins.

P. Caillet-Fauquet, Manoussos Perros, Annick Brandenburger et al. · The EMBO Journal · 1990 · 176 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +11

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

Karsten Geletneky, Johannes Huesing, Jean Rommelaere et al. · BMC Cancer · 2012 · 159 citations · Full text

Medicine, Oncology, Surgery +15

Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells

Matteo Piazza, Carmen Mader, Karsten Geletneky et al. · Journal of Virology · 2007 · 156 citations · Full text

Life Sciences, Molecular Biology, Oncology +17